Zura Bio stock fell 4.38 percent as Phase 2 data approach

Published on 10/05/2026 at 23:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zura Bio stock was last at USD 3.93 on October 5, 2026, with a USD 373.3 million market cap. Its TibuSHIELD Phase 2 study enrolled 247 patients.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio (ISIN KYG9TY5A1016) was last at USD 3.93 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, down 4.38 percent from USD 4.11. The immediate focus is the companys Phase 2 TibuSHIELD readout, with data expected in Q4 2026, according to Seeking Alpha on October 4, 2026.

247 patients set the test

The TibuSHIELD study is testing tibulizumab in hidradenitis suppurativa, a chronic inflammatory skin disease. The 247-patient trial evaluates a bispecific antibody designed to block IL-17A and BAFF, giving the upcoming readout a direct clinical benchmark, Seeking Alpha reported.

Zura Bio describes itself as a clinical-stage immunology company. Its lead candidate is also being evaluated in TibuSURE for systemic sclerosis, while the company plans to initiate NEXUS-PMR for polymyalgia rheumatica by year-end 2026.

Loss expands as analysts stay bullish

For the quarter ended June 30, 2026, Zura Bio reported a quarterly GAAP net loss of USD 26.3 million, compared with USD 15.99 million in the year-earlier quarter, according to Markets Insider on October 2, 2026. The comparison puts research spending and clinical execution at the center of the valuation debate.

MarketBeat lists a Moderate Buy consensus from seven analysts, including five Buy ratings, one Strong Buy and one Sell. Its average 12-month price target is USD 17.00, which lies 332.6 percent above the USD 3.93 reference price.

MarketBeat also reports that Guggenheim raised its target from USD 15.00 to USD 20.00 and Wedbush lifted its target from USD 15.00 to USD 22.00 in research dated August 12, 2026, keeping the analyst backdrop positive while the company remains dependent on clinical data.

Stock trades below its yearly high

Zura Bio traded within a USD 3.92 to USD 4.18 session range on October 5, 2026, with volume of 2,649,111 shares. Its USD 373.3 million market capitalization and USD 3.15 to USD 7.44 52-week range show a small-cap biotech valuation that remains below its yearly high.

For investors, the next measurable checkpoint is the TibuSHIELD data window in Q4 2026. The stock was last at USD 3.93 on Nasdaq on October 5, 2026 at 4:00 p.m. ET.